"B-1a cells have been shown to ameliorate influenza virus infection, sepsis, and pneumonia, all of which are similar to COVID-19," says Monowar Aziz and colleagues in a new review article. "B-1a cell therapy is able to mitigate the progression of these infections to ARDS, raising the possibility that B-1a cell therapy may also ameliorate ARDS associated with COVID-19."
|